PMID- 37907630
OWN - NLM
STAT- MEDLINE
DCOM- 20231103
LR  - 20231212
IS  - 1438-7948 (Electronic)
IS  - 1438-793X (Linking)
VI  - 23
IP  - 4
DP  - 2023 Nov 1
TI  - IL-1R8 expression in DLBCL regulates NK cell recruitment and influences patient 
      prognosis.
PG  - 328
LID - 10.1007/s10142-023-01254-2 [doi]
AB  - The precise biological function of Interleukin-1 receptor 8 (IL-1R8) in diffuse 
      large B-cell lymphoma (DLBCL) is still not well understood. Our goal is to 
      decipher the profile of IL-1R8 expression status in DLBCL and to explore how 
      IL-1R8 is involved in DLBCL progression. Utilizing a tissue microarray consisting 
      of 70 samples of DLBCL tumors alongside 15 samples of tonsillitis, our 
      investigation revealed a parallel expression profile of IL-1R8 between the tumor 
      tissues and tonsillitis samples (p > 0.05). Nevertheless, an intriguing 
      association emerged, as heightened expression of IL-1R8 correlated significantly 
      with unfavorable survival outcomes in patients with DLBCL (p < 0.05). The status 
      of IL-1R8 expression did not directly regulate proliferation (p > 0.05) and 
      apoptosis (p > 0.05) in DLBCL cells via CCK8 and apoptotic assays. Subsequent 
      chemotaxis analysis indicated that natural killer (NK) cell recruitment could be 
      suppressed by IL-1R8 signaling in DLBCL, at least partially through CXCL1 
      inhibition (p < 0.05). The status of IL-1R8 expression in tumor tissues exhibited 
      a negative correlation with the density of CD57+ NK cell infiltration (p < 0.05), 
      while it did not demonstrate a significant association with CD3+ T cells (p > 
      0.05), CD68+ macrophages (p > 0.05), or S-100+ dendritic cells (p > 0.05). In 
      line with this observation, elevated levels of NK cell infiltration demonstrated 
      a significant positive correlation with improved overall survival (OS) among 
      patients diagnosed with DLBCL (p < 0.05). Our data suggests the immuno-regulating 
      potential of IL-1R8 through NK cell recruitment in DLBCL, providing novel 
      insights into future immuno-modulating therapies.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Yu, Min
AU  - Yu M
AD  - Department of Hematology, First Affiliated Hospital of Nanchang University, 17 
      Yongwai Street, Nanchang, Jiangxi, 330006, China.
FAU - Zhang, Qian
AU  - Zhang Q
AD  - Department of Hematology, First Affiliated Hospital of Nanchang University, 17 
      Yongwai Street, Nanchang, Jiangxi, 330006, China.
FAU - Wan, Luying
AU  - Wan L
AD  - Department of Oncology, First Affiliated Hospital of Fujian Medical University, 
      Fuzhou, Fujian, China.
FAU - Wang, Shixuan
AU  - Wang S
AD  - Department of Hematology, First Affiliated Hospital of Nanchang University, 17 
      Yongwai Street, Nanchang, Jiangxi, 330006, China.
FAU - Zou, Lifang
AU  - Zou L
AD  - Department of Hematology, First Affiliated Hospital of Nanchang University, 17 
      Yongwai Street, Nanchang, Jiangxi, 330006, China.
FAU - Chen, Zhiwei
AU  - Chen Z
AD  - Department of Hematology, First Affiliated Hospital of Nanchang University, 17 
      Yongwai Street, Nanchang, Jiangxi, 330006, China.
FAU - Li, Fei
AU  - Li F
AD  - Department of Hematology, First Affiliated Hospital of Nanchang University, 17 
      Yongwai Street, Nanchang, Jiangxi, 330006, China. ndyfy01238@ncu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231101
PL  - Germany
TA  - Funct Integr Genomics
JT  - Functional & integrative genomics
JID - 100939343
RN  - 0 (IL1RAP protein, human)
SB  - IM
MH  - Humans
MH  - Killer Cells, Natural/pathology
MH  - *Lymphoma, Large B-Cell, Diffuse/genetics/metabolism/pathology
MH  - Macrophages/metabolism
MH  - Signal Transduction
MH  - *Tonsillitis/metabolism/pathology
OTO - NOTNLM
OT  - DLBCL
OT  - Diffuse large B-cell lymphoma
OT  - IL-1R8
OT  - Natural killer cell
EDAT- 2023/11/01 06:43
MHDA- 2023/11/02 12:42
CRDT- 2023/11/01 00:40
PHST- 2023/08/24 00:00 [received]
PHST- 2023/10/13 00:00 [accepted]
PHST- 2023/10/05 00:00 [revised]
PHST- 2023/11/02 12:42 [medline]
PHST- 2023/11/01 06:43 [pubmed]
PHST- 2023/11/01 00:40 [entrez]
AID - 10.1007/s10142-023-01254-2 [pii]
AID - 10.1007/s10142-023-01254-2 [doi]
PST - epublish
SO  - Funct Integr Genomics. 2023 Nov 1;23(4):328. doi: 10.1007/s10142-023-01254-2.